Camera Catches Melanoma at Early Stage

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

The SIAscope uses light and sophisticated computer software to construct an image of each part of the skin. The technique shows when a mole is invading deeper into the skin than normal, allowing early diagnosis of malignant melanoma. The SIAscope, based on spectrophotometric intracutaneous analysis (SIA), was researched at Birmingham University and developed by Cambridge-based Astron Clinica. It is in clinical trials at various sites in the United Kingdom. Dr. Marc Moncrieff (pictured, left) is one of the doctors conducting the trials.

The SIAscope uses light and sophisticated computer software to construct an image of each part of the skin. The technique shows when a mole is invading deeper into the skin than normal, allowing early diagnosis of malignant melanoma. The SIAscope, based on spectrophotometric intracutaneous analysis (SIA), was researched at Birmingham University and developed by Cambridge-based Astron Clinica. It is in clinical trials at various sites in the United Kingdom. Dr. Marc Moncrieff (pictured, left) is one of the doctors conducting the trials.

Articles in this issue
Irinotecan Plus Cisplatin May Be a Promising Radiation Sensitizer, According to Phase II Study
Major Trial of Four Newest Chemotherapy Regimens for Advanced NSCLC Shows Comparable Survival
Irinotecan-Containing Chemotherapy Regimens Active in Pancreatic Cancer and Ovarian Cancer
Interim Results Show Similar Response Rates for TEC vs CEV in Small-Cell Lung Cancer
Scientists Identify Gene Mutations in Multiple Myeloma
Irinotecan Plus Cisplatin Results in Highly Significant Survival Improvement in Extensive-Disease Small-Cell Lung Cancer
New Analyses Establish the Addition of Irinotecan to Fluorouracil/Leucovorin as the New Standard of Care for First-Line Rx of Metastatic Colorectal Cancer
Single-Agent Herceptin Active in Metastatic Breast Cancer
Brain Metastases Respond to Paclitaxel, Carboplatin, and Brain RT
AC Comparable to CMF in ER-Negative, Node-Negative Early-Stage Breast Cancer
Herceptin/Vinorelbine Promising in Metastatic Breast Cancer
Early Phase III Results Indicate Concurrent Chemoradiation Is Promising for Treatment of Locally Advanced NSCLC
Gemcitabine/Vinorelbine Boosts Survival in Elderly NSCLC Patients
Timing Affects Chemotherapy’s Effectiveness and Tolerability in Metastatic Colon Cancer
Virtual Colonoscopy Promising for Colon Cancer Screening
Related Videos
Experts on myeloma
Related Content
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

Selecting Observation Vs Immunotherapy in Advanced Melanoma

April 2nd 2024
Article

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

FDA Clears Non-Invasive AI Device for Skin Cancer Detection

January 18th 2024
Article

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

December 18th 2023
Article

mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma.

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma

October 23rd 2023
Article

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.